Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, Poland.
Adv Exp Med Biol. 2019;1073:57-76. doi: 10.1007/978-3-030-12298-0_3.
Blood serum or plasma proteome is a gold mine of disease biomarkers. However, complexity and a huge dynamic range of their components, combined with multiple mechanisms of degradation and posttranslational modifications, further complicated by the presence of lipids, salts, and other metabolites, represent a real challenge for analytical sensitivity, resolution, and reproducibility. This problem exists particularly in the case of potential disease-specific markers, most typically represented by low-abundant proteins (LAPs), whose detection is usually impaired by the dominance of albumins, immunoglobulins, and other high-abundant serum/plasma proteins (HAPs). Hence, analysis of biomarker candidates in serum/plasma samples frequently requires separation of their components, usually including depletion of albumin in a fraction of interest. Such "preprocessing" of serum/plasma specimens is critical in proteomic analysis based on mass spectrometry. This approach is very potent; nevertheless a wide range of protein concentrations in serum/plasma represents a particular challenge, since high-abundant proteins (mostly albumin) dominate in a sample subjected to mass spectrometry and suppress peptide ions originating from low-abundant proteins, thus limiting probability and reliability of their detection. An emerging approach in serum-/plasma-based biomarker-oriented studies is the proteome component of exosomes - nanovesicles secreted by cells and involved in multiple aspects of intercellular communication. However, the presence of albumin, frequent contaminant of exosomes isolated from human serum/plasma, represents a real challenge also in this type of study. A similar problem is encountered in proteomic studies based on exosomes obtained in in vitro experiments where culture media are normally supplemented with fetal bovine serum containing growth factors and hormones. In this case exosomes are frequently contaminated with bovine serum albumin and other bovine serum proteins which should be removed before proteomic analysis of exosome cargo.
血清或血浆蛋白质组是疾病生物标志物的金矿。然而,其成分的复杂性和巨大动态范围,加上多种降解和翻译后修饰机制,以及脂质、盐和其他代谢物的存在,对分析灵敏度、分辨率和重现性构成了真正的挑战。在潜在疾病特异性标志物的情况下,尤其是低丰度蛋白 (LAP) ,这种情况尤其如此,其检测通常因白蛋白、免疫球蛋白和其他高丰度血清/血浆蛋白 (HAP) 的主导而受到损害。因此,血清/血浆样品中生物标志物候选物的分析通常需要分离其成分,通常包括感兴趣分数中白蛋白的耗尽。这种“预处理”对于基于质谱的蛋白质组学分析至关重要。这种方法非常有效;然而,血清/血浆中广泛的蛋白质浓度代表了一个特别的挑战,因为高丰度蛋白质(主要是白蛋白)在进行质谱分析的样品中占主导地位,并抑制来自低丰度蛋白质的肽离子,从而限制了它们检测的可能性和可靠性。在基于血清/血浆的生物标志物导向研究中,一种新兴的方法是外泌体的蛋白质组成分-细胞分泌的纳米囊泡,参与细胞间通讯的多个方面。然而,白蛋白的存在是此类研究中也面临的一个真正挑战,白蛋白是从人血清/血浆中分离出的外泌体的常见污染物。在基于体外实验获得的外泌体的蛋白质组学研究中也存在类似的问题,其中通常在培养基中补充含有生长因子和激素的胎牛血清。在这种情况下,外泌体经常被牛血清白蛋白和其他牛血清蛋白污染,在对外泌体货物进行蛋白质组学分析之前,这些蛋白质应该被去除。